Anti-hyperlipidemic drugs are a key means of dealing with abnormal blood lipid levels. These drugs mainly act on the human body's lipid metabolism process to regulate the lipid levels in the blood. They can reduce elevated cholesterol and triglycerides, adjust the proportion of lipoproteins, thereby reducing blood viscosity and improving blood circulation. In clinical applications, anti-hyperlipidemic drugs can effectively reduce the risk of cardiovascular diseases such as myocardial infarction and stroke. They are an important line of defense in the prevention and treatment of hyperlipidemia and its complications, helping to maintain the health of the human cardiovascular system.
-
![(4R,6R)-tert-Butyl-6-cyaanmethyl-2,2-dimethyl-1,3-dioxaan-4-acetaat CAS-NR.{{ 10}}]()
(4R,6R)-tert-Butyl-6-cyaanmethyl-2,2-dimethyl-1,3-dioxaan...MF:C14H23NO4. Mw: 269,34. EINECS:425-780-3. -
![Tert-butyldimethylsilylchloride CAS-NR.18162-48-6]()
Tert-butyldimethylsilylchloride CAS-NR.18162-48-6Silaan reagentia; koppelingsreagentia; organometallische reagentia; condensatie reagentia; silicium verbindingen; chloorsilanen; beschermde aminozuren; silaan reagentia; bescherming en -
![N-[5-Bromomethyl-4-(4-fluorofenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethaan Sulfonamide CAS NO.799842-07-2]()
N-[5-Bromomethyl-4-(4-fluorofenyl)-6-isopropylpyrimidine-...Hoewel Z8-2 is niet zo populair als de tussenliggende in de eerste paar stappen, het is ook een onmisbare intermediair. In de afgelopen jaren is de marktvraag naar Z8-2 geleidelijk aan gegroeid, en -
![Rosuvastatine Calcium Intermediair D5 CAS NO.154026-95-6]()
Rosuvastatine Calcium Intermediair D5 CAS NO.154026-95-6Farmaceutische tussenproducten; rosuvastatine calcium tussenproducten; synthetische materiaaltussenproducten -
![Methyl Isobutyrylacetaat (MIBA) CAS NR. 4258-54-3]()
Methyl Isobutyrylacetaat (MIBA) CAS NR. 4258-54-3MF: C7H12O3 . MW: 144.17 . EINECS: 418-900-0 -
![Atorvastatine Acetonide tert-Butyl Ester CAS NR. 125971-95-1]()
Atorvastatine Acetonide tert-Butyl Ester CAS NR. 125971-95-1MF: C40H47FN2O5. MW: 654,81. EINECS-certificaat: 258-925-2 -
![3- (Broommethyl) -2-cyclopropyl-4- (4'-fluorfenyl) chinoline CAS NR. 154057-56-4]()
3- (Broommethyl) -2-cyclopropyl-4- (4'-fluorfenyl) chinol...MF: C19H15BrFN . MW: 356,23 . EINECS: 686-743-7 -
![[2-Cyclopropyl-4- (4-fluorfenyl) -chinoline-3-ylmethyl] -trifenyl-fosfonium Bromido CAS NR. 154057-58-6]()
[2-Cyclopropyl-4- (4-fluorfenyl) -chinoline-3-ylmethyl] -...MF: C37H30BrFNP . MW: 618.5169642 . EINECS: 1312995-182-4 -
![T-Butyl (3R, 5S) -7- [2-cyclopropyl-4- (4-fluorfenyl) chinoline-3-yl] -3,5-isopropylideendioxy-6-heptenoaat (PB4) CAS NR.586966-54-3]()
T-Butyl (3R, 5S) -7- [2-cyclopropyl-4- (4-fluorfenyl) chi...MF: C32H36FNO4 . MW: 517.637 . EINECS: 1592732-453-0 -
![Pitavastatin Tert-Butyl Ester CAS NO.586966-54-3]()
Pitavastatin Tert-Butyl Ester CAS NO.586966-54-3MF: C29H32FNO4 . MW: 477.573 . EINECS: 1308068-626-2 -
![(4R-Cis)-6-Hydroxymethyl-2,2-dimethyl-1,3-dioxaan-4-azijnzuur 1,1-dimethylethylester CAS NR.124665-09-0]()
(4R-Cis)-6-Hydroxymethyl-2,2-dimethyl-1,3-dioxaan-4-azijn...MF: C13H24O5. Maa: 260,33. EINECS-certificaat: 432-960-5 -
![Tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxaan-4-acetaat CAS NR.124752-23-4]()
Tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-diox...MF: C13H22O5. Ma-W: 258,31. EINECS-certificaat: 1308068-626-2
![N-[5-Bromomethyl-4-(4-fluorofenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethaan Sulfonamide CAS NO.799842-07-2](/uploads/202224095/small/n-5-bromomethyl-4-4-fluorophenyl-625079637964.png?size=380x0)
![[2-Cyclopropyl-4- (4-fluorfenyl) -chinoline-3-ylmethyl] -trifenyl-fosfonium Bromido CAS NR. 154057-58-6](/uploads/202224095/small/2-cyclopropyl-4-4-fluorophenyl-quinolin-312354620752.png?size=380x0)
![T-Butyl (3R, 5S) -7- [2-cyclopropyl-4- (4-fluorfenyl) chinoline-3-yl] -3,5-isopropylideendioxy-6-heptenoaat (PB4) CAS NR.586966-54-3](/uploads/202224095/small/t-butyl-3r-5s-7-2-cyclopropyl-4-423061586456.png?size=380x0)
Classification of Anti-hyperlipidemic Drugs
Anti-hyperlipidemic drugs can be mainly classified into the following categories
They reduce cholesterol synthesis by inhibiting HMG - CoA reductase and increase the expression of LDL receptors at the same time. They have a strong effect on reducing LDL - C.
They activate PPAR and enhance the activity of LPL, significantly reducing TG and slightly increasing HDL - C.
For example, PCSK9 inhibitors reduce LDL - C by inhibiting the PCSK9 protein and increasing the number of LDL receptors.
A: We strictly control the product quality. All products are rigorously tested. The purity standards vary for different products. The purity of most products is 90%, ensuring that they meet the relevant industry standards and customers' needs.
We're well-known as one of the leading anti hyperlipidemia drugs manufacturers and suppliers in China. Our factory offers high quality anti hyperlipidemia drugs made in China with competitive price. Welcome to contact us for wholesale service.
